Zofran and Hepatocellular damage - a phase IV clinical study of FDA data

Summary:

Hepatocellular damage is reported as a side effect among people who take Zofran (ondansetron hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Hepatocellular damage when taking Zofran. It is created by eHealthMe based on reports of 93,713 people who have side effects when taking Zofran from the FDA, and is updated regularly.

What is Zofran?

Zofran has active ingredients of ondansetron hydrochloride. It is often used in nausea. eHealthMe is studying from 94,987 Zofran users. Check the latest studies of Zofran.

What is Hepatocellular damage?

Hepatocellular damage (liver damage) is found to be associated with 512 drugs and 610 conditions by eHealthMe. Check the latest studies of Hepatocellular damage.

On Jul, 12, 2026

93,713 people reported to have side effects when taking Zofran.
Among them, 30 people (0.03%) have Hepatocellular damage.

Could Zofran cause Hepatocellular damage?

Among these 30 people:

How long have people been on Zofran when they have Hepatocellular damage? *

What is the gender of people who have Hepatocellular damage when taking Zofran? *

female: 20 %
male: 80 %

What is the age of people who have Hepatocellular damage when taking Zofran? *

What are other drugs people take besides Zofran? *

What are other side effects people have besides Hepatocellular damage? *

Fatigue (feeling of tiredness): 11 people, 36.67%
Multi-Organ Failure (multisystem organ failure): 9 people, 30.00%
Clamminess (moist, sticky, and cold to the touch): 8 people, 26.67%
Dehydration (dryness resulting from the removal of water): 8 people, 26.67%
Cardiac Arrest: 8 people, 26.67%
Hypokalemia (low potassium): 7 people, 23.33%
Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 6 people, 20.00%
Fever: 6 people, 20.00%
Anuria (failure of the kidneys to produce urine): 6 people, 20.00%
Acute Kidney Failure: 6 people, 20.00%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 10.00%
Post Procedural Pain: 2 people, 6.67%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 6.67%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 6.67%
Ventricular Flutter (arrhythmia): 1 person, 3.33%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 3.33%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 1 person, 3.33%
Depression: 1 person, 3.33%
Cancer - Throat Or Larynx: 1 person, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Zofran and have Hepatocellular damage?

- Check whether Hepatocellular damage is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zofran:

Zofran (94,987 reports)

Browse all side effects of Zofran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatocellular damage:

Hepatocellular damage (512 drugs)

Browse all the conditions that are associated with Hepatocellular damage:

Hepatocellular damage (610 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ondansetron hydrochloride (the active ingredients of Zofran) and Zofran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.